Restless Legs Syndrome in Adults 18+ When First-Line Treatment Has Not Achieved Adequate Control

This protocol applies to adults aged 18 years or older with restless legs syndrome (RLS), in the absence of end-stage renal disease, whose first-line pharmacotherapy did not produce clinically significant improvement in disease severity, sleep quality, and quality of life.

Patient population

Adults 18 years or older with restless legs syndrome, without end-stage renal disease, who have not met the treatment goals of the initial therapeutic line.

First-line failure — escalation criterion

The preceding step involved an alpha-2-delta ligand — gabapentin enacarbil, gabapentin, or pregabalin — or, in patients with appropriate iron status, IV ferric carboxymaltose. Escalation to this next-line protocol is indicated when that initial therapy fails to achieve clinically significant improvement in RLS disease severity, sleep quality, and quality of life.

Next-line approach (partial overview)

For refractory RLS in this population, conditionally recommended options include iron-based therapies for patients meeting specific iron-status criteria, as well as other pharmacological and neuromodulatory interventions. The complete sequenced regimen — including which option to select and under what conditions — is available via the link below.

Treatment goal: Clinically significant improvement in restless legs syndrome disease severity.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.5664/jcsm.11390

Recommendations for specific interventions for the treatment of adults with RLS are presented below.

In adults with RLS, the AASM recommends the use of gabapentin enacarbil over no gabapentin enacarbil (strong recommendation, moderate certainty of evidence).

In adults with RLS, the AASM suggests the use of IV low molecular weight iron dextran over no IV low molecular weight iron dextran in patients with appropriate iron status (see good practice statement for iron parameters) (conditional recommendation, very low certainty of evidence).

In adults with RLS, the AASM suggests the use of ferrous sulfate over no ferrous sulfate in patients with appropriate iron status (see good practice statement for iron parameters) (conditional recommendation, moderate certainty of evidence).

In adults with RLS, the AASM suggests the use of bilateral high-frequency peroneal nerve stimulation over no peroneal nerve stimulation (conditional recommendation, moderate certainty of evidence).

View source ↗